

2011

Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities

Anil Kumar
University of Rhode Island

Israr Ahmad

See next page for additional authors

Creative Commons License

[Creative Commons License](#)

This work is licensed under a [Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License](#).

Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs

This is a pre-publication author manuscript of the final, published article.

Citation/Publisher Attribution

Kumar, A., Ahmad, I., Chhikara, B. S., Tiwari, R., Mandal, D., & Parang, K. (2011). Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities. *Bioorganic & Medicinal Chemistry Letters*, 21(5), 1342-1346. doi: 10.1016/j.bmcl.2011.01.047

Available at: <https://doi.org/10.1016/j.bmcl.2011.01.047>

This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at DigitalCommons@URI. It has been accepted for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons@etal.uri.edu.

Authors

Anil Kumar, Israr Ahmad, Bhupender S. Chhikara, Rakesh Tiwari, Deendayal Mandal, and Keykavous Parang

2011

Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole Conjugates and Evaluation of Their Src Kinase Inhibitory and Anticancer Activities

Anil Kumar

Birla Institute of Technology and Science (BITS)

Israr Ahmad

Birla Institute of Technology and Science (BITS)

Bhupender S. Chhikara

University of Rhode Island


Rakesh Tiwari

Chapman University, tiwari@chapman.edu

Deendayal Mandal

University of Rhode Island

Follow this and additional works at: http://digitalcommons.chapman.edu/pharmacy_articles

 *next page for additional authors*
Part of the [Chemicals and Drugs Commons](#), [Immune System Diseases Commons](#), [Medical Biochemistry Commons](#), [Medicinal and Pharmaceutical Chemistry Commons](#), and the [Oncology Commons](#)

Recommended Citation

Kumar, Anil, et al. "Synthesis of 3-phenylpyrazolopyrimidine-1, 2, 3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities." *Bioorganic & medicinal chemistry letters* 21.5 (2011): 1342-1346. doi: 10.1016/j.bmcl.2011.01.047

This Article is brought to you for free and open access by the School of Pharmacy at Chapman University Digital Commons. It has been accepted for inclusion in Pharmacy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more information, please contact laughtin@chapman.edu.

Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole Conjugates and Evaluation of Their Src Kinase Inhibitory and Anticancer Activities

Comments

NOTICE: this is the author's version of a work that was accepted for publication in *Bioorganic & Medicinal Chemistry Letters*. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in *Bioorganic & Medicinal Chemistry Letters*, volume 21, issue 5, in 2011. DOI: [10.1016/j.bmcl.2011.01.047](https://doi.org/10.1016/j.bmcl.2011.01.047)

The Creative Commons license below applies only to this version of the article.

Creative Commons License



This work is licensed under a [Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Copyright

Elsevier

Authors

Anil Kumar, Israr Ahmad, Bhupender S. Chhikara, Rakesh Tiwari, Deendayal Mandal, and Keykavous Parang

Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities

Anil Kumar,^{a,b,*} Israr Ahmad,^a Bhupender S. Chhikara,^b Rakesh Tiwari,^b Deendayal Mandal,^b and Keykavous Parang^{b,*}

^aDepartment of Chemistry, Birla Institute of Technology and Science, Pilani 333 031, Rajasthan, India

^bDepartment of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881 USA

Received Month XX, 2000; Accepted Month XX, 2000 [BMCL RECEIPT]

Abstract—A series of two classes of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates were synthesized using click chemistry approach. All compounds were evaluated for inhibition of Src kinase and human ovarian adenocarcinoma (SK-Ov-3), breast carcinoma (MDA-MB-361), and colon adenocarcinoma (HT-29). Hexyl triazolyl-substituted 3-phenylpyrazolopyrimidine exhibited inhibition of Src kinase with an IC₅₀ value of 5.6 μM. 4-Methoxyphenyl triazolyl-substituted 3-phenylpyrazolopyrimidine inhibited the cell proliferation of HT-29 and SK-Ov-3 by 73% and 58%, respectively, at a concentration of 50 μM.

Phosphorylation of many protein substrates occurs in the presence of protein tyrosine kinases (PTKs) that catalyze the transfer of γ-phosphate group from ATP to specific tyrosine residues. PTKs have critical roles in the signal transduction pathways. Src family kinases (SFKs) are a family of nine different PTKs, including c-Src, c-Yes, Fyn, Lck, Lyn, Hck, Frk, Blk, and c-Fgr of which Src is the prototype.¹ SFKs have important roles in the regulation of a wide variety of normal cellular signal transduction pathways, such as cell division, growth factor signaling, differentiation, survival, adhesion, migration, and invasion.² Src tyrosine kinase expression is frequently elevated in a number of epithelial tumors including colon, breast, prostate, lung, ovary, and pancreas compared with the adjacent normal tissues. Src kinase is a key modulator of cancer cell invasion and metastasis.³⁻⁶

In recent years development of Src kinase inhibitors for the treatment of cancer is a subject of major interest.⁷ A number of inhibitors of protein kinases⁸ such as quinazolines,⁹ quinuclidinylcarbonitriles,¹⁰ pyrazolopyrimidines,¹¹ imidazo[1,5-*d*]pyrazines,¹² benzotriazines,¹³ ATP-phosphopeptide conjugates,¹⁴ pyrimidoquinolines,¹⁵ and pyridopyrimidinones¹⁶ have been investigated for the treatment of cancer, chronic inflammatory diseases, and other indications.¹⁷ Imatinib

is a 2-phenylaminopyrimidine nonselective PTK inhibitor of ABL, c-Kit, and PDGFR approved for the treatment of a number of malignancies like chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GISTs).¹⁸ However, various imatinib-resistant mutations are generated spontaneously on Abl over long-term course of treatment.¹⁹ Dasatinib (BMS-354825) is a pyrimidinylthiazole-based ATP-competitive dual SRC/ABL inhibitor²⁰ approved to use in patients with CML after imatinib treatment. Bosutinib (SKI-606), a 3-quinolinecarbonitrile-based Src kinase inhibitor, is known to suppress migration and invasion of human breast cancer cells.²¹

Crystallographic studies of an ATP mimic, AMP-PNP, bound to c-Src (PDB 2SRC)²² and complexes of 3-phenylpyrazolopyrimidine derivatives (PP1 and PP2) (Fig. 1) as ATP-binding site inhibitors with Hck (PDB 1QCF)²³ and Lck (PDB 1QPE)²⁴ have revealed that the pyrazolopyrimidine core of PP1 and PP2 mimic the adenine base of ATP in binding to the nucleotide binding site. We have previously shown that 3-phenyl group contributes significantly to Src kinase inhibitory activity through a hydrophobic interaction with a large hydrophobic pocket in the ATP-binding site.^{25a} Another cavity is formed from side chains of helix αC and helix αD. This cavity is normally occupied

by carbohydrate moiety followed by triphosphate group of ATP and remains mostly unfilled by *tert*-butyl of 3-phenylpyrazolopyrimidines (PP1 and PP2).

In continuation of our efforts to design or identify new Src kinase inhibitors,^{14,25} we investigated whether that variation of N₁ substitution in 3-phenylpyrazolopyrimidines with different 1,2,3-triazoles containing hydrophobic residues can occupy and/or interact with amino acids of this cavity and contribute to the enhancement of Src kinase inhibitory potency. Herein, we describe synthesis and evaluation of Src kinase inhibitory activity of two classes of 3-phenylpyrazolopyrimidine (PhPP)-1,2,3-triazole conjugates (Fig. 1), in which the pyrazolo ring of PhPP is attached through an ethylene or a methylene linker to positions 1 and 4 of the triazole, respectively. All the compounds were synthesized under click reaction conditions.





Figure 1. Chemical structures of 3-phenylpyrazolopyrimidines and 1,4-disubstituted 1,2,3-triazoles.


Synthesis of PhPP scaffolds (**7a-b**) was achieved according to the previously reported procedure with slight modification as shown in Scheme 1.^{25,26} 2-Benzoylmalononitrile (**3**) was synthesized from the reaction of benzoyl chloride (**1**) with malononitrile (**2**) in the presence of sodium hydride in THF. Methylation of **3** with dimethyl sulfate in the presence of sodium bicarbonate in dioxane afforded 2-(methoxyphenylmethylene)malononitrile (**4**), which was cyclized by treatment with hydrazine hydrochloride or 2-hydroxyethyl hydrazine in the presence of triethylamine to afford 5-amino-3-phenyl-1H-pyrazole-4-carbonitrile (**6a**) or 5-amino-1-(2-hydroxyethyl)-3-phenyl-1H-pyrazole-4-carbonitrile (**6b**), respectively. Reaction of (**6a-b**) with formamide at 180 °C for 24 h afforded the corresponding PhPP scaffolds **7a** and **7b** in 72 and 76% yields, respectively.




Scheme 1. Synthesis of N¹-substituted PhPP scaffolds.

Compounds **7b** and **7a** were used for the synthesis of azido- and alkyne-substituted building blocks **9** and **12**, respectively, needed for click reactions. Synthesis of compound **9** was carried out by mesylation of **7b** followed by nucleophilic substitution with sodium azide in DMF (Scheme 2). Compound **12** was prepared by the reaction of **7a** with propargyl bromide in the presence of potassium carbonate in acetone at room temperature (Scheme 3). Only the N₁-endocyclic amino group of PhPP derivatives was reacted with propargyl bromide. Unprotected N₄-exocyclic amine was not reactive under these reaction conditions as shown previously.²⁷

Two classes of PhPP-1,2,3-triazole conjugates (**11a-i** and **14a-j**) were prepared by the click chemistry approach using regioselective addition of **9** with different alkynes (**10a-i**) (Scheme 2) and **12** with different azides (**13a-k**) (Scheme 3) catalyzed by *in situ* generated copper(I) salt at room temperature. The reactions proceeded in high yields (76-88%) and in a regioselective manner. All the compounds were purified using column chromatography and characterized by ¹H NMR, ¹³C NMR, and HRMS spectroscopy. The IR spectra of the compounds (**14a-j**) exhibited a strong band at about 1685 cm⁻¹ confirming the presence of a carbonyl group. In ¹H NMR spectra of **11a-i** and **14a-j** a characteristic singlet was observed for triazolyl C₅-H at about δ 7.90 ppm.



Scheme 2. Synthesis of PhPP-1,2,3-triazole conjugates **11a-i**.




Scheme 3. Synthesis of PhPP-1,2,3-triazole conjugates **14a-j**.

An array of 20 diversely substituted PhPP-1,2,3-triazole conjugates were evaluated against Src kinase. The results of Src kinase inhibitory activity of compounds in classes 1 (**11a-i**) and 2 (**14a-j**) are shown in Tables 1 and 2, respectively.

All compounds in class 1 showed less inhibitory activities when compared with that of PP2. A number of compounds **11b**, **11f**, and **11g** showed modest inhibitory activity ($IC_{50} = 5.6$ – $29.6 \mu\text{M}$) (Table 1). These data suggest that the presence of 1,2,3-triazole-substituted with bulky groups and attached through an ethylene to PhPP scaffold is less tolerated, possibly because the cavity cannot accommodate large groups. Furthermore, the substitutions may not be oriented appropriately in the cavity or may have unfavorable interactions.

Table 1. The Src kinase inhibitory activities of compounds **11a–i** (class 1).



Comps	R	IC_{50} (μM) ^a	Log P (Calcd) ^c
9	-	6.2	-
11a	$\text{CH}_3(\text{CH}_2)_5\text{CH}_2$ -	>75	2.83
11b	$\text{CH}_3(\text{CH}_2)_6\text{CH}_2$ -	5.6	3.89
11c	$\text{CH}_3(\text{CH}_2)_7\text{CH}_2$ -	>75	4.41
11d	$\text{CH}_3(\text{CH}_2)_8\text{CH}_2$ -	>75	5.47
11e	$\text{C}_6\text{H}_5\text{CH}_2$ -	NA ^b	2.81
11f	4- $\text{CH}_2\text{OC}_6\text{H}_4$ -	17.4	3.06
11g	4- FC_6H_4 -	29.6	3.25
11h	4- $\text{CH}_2\text{COC}_6\text{H}_4$ -	>75	2.60
11i	- $\text{CH}_2\text{CH}_2\text{CH}_2\text{Cl}$	NA	2.01
Staurosporine	-	0.3	-
PP2	-	2.8	3.57


^aThe concentration that inhibited enzyme activity by 50%; ^bless than 10% enzyme inhibitory activity was observed up to the concentration of 250 μM ; ^cCalculated partition coefficient using ChemBioDraw Ultra 12.0.






Compounds in class 2 exhibited more diverse inhibitory activities (Table 2). Compounds **14e**, **14f**, **14i**, and **14j** demonstrated modest Src inhibitory activities with IC_{50} values between 9.1 and 23.1 μM . 1,2,3-Triazole-substituted with naphthyl (**14h**), tolyl (**14c**), and 4-chlorophenyl (**14a** and **14g**) showed significantly weak inhibitory potency, suggesting incorporation of bulky groups are less tolerated in the cavity. The presence of 1,2,3-triazole between PhPP scaffold and the substitution through a carbonyl group provides less flexibility for the substituted moieties at N_1 position to be accommodated into cavity.

Molecular modeling and minimization was used to explore how the structures would fit within the ATP-binding site of the enzyme (Fig. 2). The modeling studies indicated that phenyl groups in **11b** and **14f** occupy the hydrophobic binding pocket similar to tolyl group of PP1 with slightly different orientations (Fig. 2). In case of **11b**, the flexible hexyl group is oriented towards the hydrophobic pocket possibly because of favorable hydrophobic interactions. On the other hand, the fluorophenyl group in **14f** is positioned towards the large cavity where the triphosphate group of ATP

usually binds similar to that of *t*-butyl group of PP1, possibly because the amide moiety in **14f** does not allow flexibility seen in **11b**.

Table 2. The Src kinase inhibitory activities of compounds **14a–j** (class 2).



Comps	R	IC_{50} (μM) ^a	Log P (Calcd) ^c
14a	4- $\text{Cl-C}_6\text{H}_4$ -	>75	2.89
14b	C_6H_5 -	>75	2.11
14c	4- $\text{CH}_3\text{C}_6\text{H}_5$ -	>75	2.60
14d		>75	1.88
14e		23.1	1.82
14f		16.4	2.22
14g		>75	2.79
14h		NA ^b	3.83
14i	- $\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$	9.1	0.32
14j	$\text{CH}_3\text{CH}_2\text{O-}$	12.7	1.35
Staurosporine	-	0.3	-
PP2	-	2.8	-

^aThe concentration that inhibited enzyme activity by 50%; ^bless than 10% enzyme inhibitory activity was observed up to the concentration of 250 μM ; ^cCalculated partition coefficient using ChemBioDraw Ultra 12.0.




Figure 2. Comparison of structural complexes of Src kinase with different PhPP derivatives. **11b** (green), PP1 (blue), and (b) **14f** (red) based on molecular modeling. The compounds and side chains of amino acids are rendered in stick styles. Compounds are in the lowest energy conformers predicted. The Figure is drawn using the Accelrys visualization system.




Figure 3. Inhibition of HT-29, MDA-MB-361, and SK-Ov-3 cell proliferation by compounds **11a-i** and **14a-j** (50 μ M) after 72 h incubation. The results are shown as the percentage of the control DMSO that has no compound (set at 100%). All the experiments were performed in triplicate.

The effect of the inhibitors at the concentration of 50 μ M on the cell proliferation of cancer cells that overexpress c-Src was also evaluated against human ovarian adenocarcinoma cells (SK-Ov-3), breast carcinoma (MDA-MB-361), and colon adenocarcinoma (HT-29) cell lines (Fig. 3). All three cell lines express highly activated Src.^{28,29} Compounds **11f** and **11i** inhibited the cell proliferation of colon cancer cells (HT-29) by 73% and 57%, respectively, (Figure 3) whereas compounds **11f** and **14h** inhibited the growth of ovarian cancer cells (SK-Ov-3) by approximately 58% and 48%, respectively (Fig. 3). Compounds **11g** and **14e** were able to inhibit the cell proliferation of breast cancer cells (MDA-MB-361) by 49% and 51%, respectively (Fig. 3).

There were some correlation between Src kinase inhibitory potency of the compounds and the growth inhibition of cancer cells since compounds **11f**, **11g**, **14e**, and **14f** were modest Src kinase inhibitors. The data suggest that modest Src inhibition may lead to anticancer activities of these compounds, but this correlation is not always perfect possibly because of the diversity in solubility (see calculated Log P values in Tables 1 and 2) and cellular uptake of these compounds in these cell lines as **11b** a modest Src kinase inhibitor was not a potent inhibitor of cell proliferation.

In summary, compounds **11b** and **14i** exhibited modest inhibitory potency ($IC_{50} = 5.6-9.1 \mu$ M) against Src kinase. Structure-activity relationship studies suggested that the incorporation of bulky groups at N₁ position of PhPP is less tolerated. 4-Methoxyphenyl triazolyl-substituted 3-phenylpyrazolo-pyrimidine (**11f**)

inhibited the cell proliferation of HT-29 by 73% at a concentration of 50 μ M. The data provide insights for further optimization of these compounds as Src kinase inhibitors and/or anticancer agents.

Acknowledgments

We acknowledge Department of Science and Technology, New Delhi Project # SR-FTP-CS-34-2007, the American Cancer Society Grant # RSG-07-290-01-CDD, and National Science Foundation, Grant Number CHE 0748555 for the financial support.

Supplementary data

Supplementary data including experimental procedures and characterization of compounds can be found in the online version of this article.

References

- 1 Yeatman, T. J. *Nat. Rev. Cancer* **2004**, *4*, 470.
- 2 Summy J. M.; Gallick, G. E. *Cancer Metastasis Rev.* **2003**, *22*, 337.
- 3 Frame, M. C. *Biochim. Biophys. Acta* **2002**, *1602*, 114.
- 4 (a) Irby, R. B.; Yeatman, T. J. *Oncogene*, **2000**, *19*, 5636. (b) Summy, J. M.; Gallick, G. E. *Clin. Cancer Res.* **2006**, *12*, 1398.
- 5 Biscardi, J. S.; Ishizawar, R. C.; Silva, C. M.; Parsons, S. J. *Breast Cancer Res.* **2000**, *2*, 203.
- 6 Fizazi, K. *Ann. Oncol.* **2007**, *18*, 1765.

- 7 Cohen, P. *Nat. Rev. Drug Disc.* **2002**, *1*, 309.
- 8 (a) Ye, G.; Tiwari, R.; Parang, K. *Curr. Opin. Investig. Drugs* **2008**, *9*, 605. (b) Parang, K.; Sun, G. *Expert Opin. Ther. Patents*, **2005**, *15*, 1183.
- 9 (a) de Vries, T. J.; Mullender, M. G.; van Duin, M. A.; Semeins, C. M.; James, N.; Green, T. P.; Everts, V.; Klein-Nulend, J. *Mol. Cancer Res.* **2009**, *7*, 476. (b) Plé, P. A.; Green, T. P.; Hennequin, L. F.; Curwen, J.; Fennell, M.; Allen, J.; Brempt, C. L.; Costello, G. *J. Med. Chem.* **2004**, *47*, 871.
- 10 Tsou, H. R.; Overbeek-Klumpers, E. G.; Hallett, W. A.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Michalak, R. S.; Nilakantan, R.; Discafani, C.; Golas, J.; Rabindran, S. K.; Shen, R.; Shi, X.; Wang, Y. F.; Upeplacis, J.; Wissner, A. *J. Med. Chem.* **2005**, *48*, 1107.
- 11 Hanke, J. H.; Gardner, J. P.; Dow, R. L.; Changelian, P. S.; Brissette, W. H.; Weringer, E. J.; Pollok, B. A.; Connelly, P. A. *J. Biol. Chem.* **1996**, *271*, 695.
- 12 (a) Mukaiyama, H.; Nishimura, T.; Kobayashi, S.; Ozawa, T.; Kamada, N.; Komatsu, Y.; Kikuchi, S.; Oonota, H.; Kusama, H. *Bioorg. Med. Chem.* **2007**, *15*, 868. (b) Mulvihill, M. J.; Ji, Q. S.; Werner, D.; Beck, P.; Cesario, C.; Cooke, A.; Cox, M.; Crew, A.; Dong, H.; Feng, L.; Foreman, K. W.; Mak, G.; Nigro, A.; O'Connor, M.; Saroglou, L.; Stolz, K. M.; Sujka, I.; Volk, B.; Weng, Q.; Wilkes, R. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 1091.
- 13 Noronha, G.; Barrett, K.; Cao, J.; Dneprovskaja, E.; Fine, R.; Gong, X.; Gritzen, C.; Hood, J.; Kang, X.; Klebansky, B.; Li, G.; Liao, W.; Lohse, D.; Mak, C. C.; McPherson, A.; Palanki, M. S. S.; Pathak, V. P.; Renick, J.; Soll, R.; Splittgerber, U.; Wrasidlo, W.; Zeng, B.; Zhao, N.; Zhou, Y. *Bioorg. Med. Chem. Lett.* **2006**, *16*, 5546.
- 14 Nam, N. H.; Lee, S.; Ye, G.; Sun, G.; Parang, K. *Bioorg. Med. Chem.* **2004**, *12*, 5753.
- 15 Boschelli, D. H.; Powell, D.; Golas, J. M.; Boschelli, F. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 2977.
- 16 Vu, C. B.; Luke, G. P.; Kawahata, N.; Shakespeare, W. C.; Wang, Y.; Sundaramoorthi, R.; Metcalf, C. A.; Keenan, T. P.; Pradeepan, S.; Corpuz, E.; Merry, T.; Bohacek, R. S.; Dalgarno, D. C.; Narula, S. S.; van Schravendijk, M. R.; Ram, M. K.; Adams, S.; Liou, S.; Keats, J. A.; Violette, S. M.; Guan, W.; Weigele, M.; Sawyer, T. K. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 3071.
- 17 Jallal, H.; Valentino, M. -L.; Chen, G.; Boschelli, F.; Ali, S.; Rabbani, S. A. *Cancer Res.* **2007**, *67*, 1580.
- 18 Corless, C. L.; Fletcher, J. A.; Heinrich, M. C. *J. Clin. Oncol.* **2004**, *22*, 3813.
- 19 Longley, D. B.; Johnston, P. G. *J. Pathology* **2005**, *205*, 275.
- 20 Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.; Sawyers, C. L. *Science*, **2004**, *305*, 399.
- 21 Vultur, A.; Buettner, R.; Kowolik, C.; Liang, W.; Smith, D.; Boschelli, F.; Jove, R. *Mol. Cancer Ther.* **2008**, *7*, 1185.
- 22 Xu, W.; Doshi, A.; Lei, M.; Eck, M. J.; Harrison, S. C. *Mol. Cell* **1998**, *3*, 629.
- 23 Schindler, T.; Sicheri, F.; Pico, A.; Gazit, A.; Levitzki, A.; Kuriyan, J. *Mol. Cell*, **1999**, *3*, 639.
- 24 Zhu, X.; Kim, J. L.; Newcomb, J. R.; Rose, P. E.; Stover, D. R.; Toledo, L. M.; Zhao, H.; Morgenstern, K. A. *Structure*, **1999**, *7*, 651.
- 25 (a) Kumar, A.; Wang, Y.; Lin, X.; Sun, G.; Parang, K. *ChemMedChem* **2007**, *2*, 1346. (b) Kumar, D.; Buchi Reddy, V.; Kumar, A.; Mandal, D.; Tiwari, R.; Parang, K. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 449. (c) Sharma, D.; Bhatia, S.; Sharma, R. K.; Tiwari, R.; Olsen, C. E.; Mandal, D.; Lehmann, J.; Parang, K.; Parmar, V. S.; Prasad, A. S. *Biochimie* **2010**, *92*, 1164. (d) Tiwari, R.; Brown, A.; Narramaneni, S.; Sun, G.; Parang, K. *Biochimie* **2010**, *92*, 1153. (e) Kumar, A.; Ye, G.; Wang, Y.; Lin, X.; Sun, G.; Parang, K. *J. Med. Chem.* **2006**, *49*, 3395. (f) Nam, N.-H.; Ye, G.; Sun, G.; Parang, K. *J. Med. Chem.* **2004**, *47*, 3131.
- 26 Hanefeld, U.; Rees, C. W. A.; White, J. P.; Williams, D. J. *J. Chem. Soc. Perkin Trans. 1* **1996**, 1545.
- 27 Burchat, A. F.; Calderwood, D. J.; Friedman, M. M.; Hirst, G. C.; Li, B.; Rafferty, P.; Ritter, K.; Skinner, B. S. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 1687.
- 28 Belches-Jablonski, A. P.; Biscardi, J. S.; Peavy, D. R.; Tice, D. A.; Romney, D. A.; Parsons, S. J. *Oncogene*, **2001**, *20*, 1465.
- 29 Budde, R. J.; Ke, S.; Levin, V. A. *Cancer Biochem. Biophys.* **1994**, *14*, 171.